Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Chief Development Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,359 |
Ending reported balance
After 2026-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 1,528 · Balance 10,915 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 556 · Balance 10,359 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,582 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Exercise / conversion · Disposed 1,528 · Balance 4,582 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 02:45 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 29,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-000586 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 218 | $1.23 | $267.18 |
DisclosureSEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,501 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 217 | $1.27 | $275.74 |
DisclosureSEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,719 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,378 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-001384 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,404 Underlying: Common Stock · 1,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 1,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 23:29 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 786 | $1.27 | $995.78 |
DisclosureSEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,558 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 23:29 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 787 | $1.39 | $1,092.59 |
DisclosureSEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,344 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:29 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000667 · form4.xml · derivative · entry 5 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:29 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,379 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000667 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,782 Underlying: Common Stock · 1,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:29 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:32 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 617 | $1.62 | $999.54 |
DisclosureSEC source: 0000905148-23-000627 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,077 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 6,497 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 6 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock · 6,497 shares Expires 2033-07-23 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F5 · kind: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F5 · price: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled. F6 · derivative.exercise_date: This Replacement Option vests as follows: 3,846 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,651 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 1,000 | Not disclosed Strike: $13.72 | Not disclosed |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 5 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2031-06-28 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F5 · kind: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F5 · price: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled. F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 5,155 | Not disclosed Strike: $20.67 | Not disclosed |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,155 shares Expires 2031-02-22 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 25,134 | Not disclosed Strike: $20.67 | Not disclosed |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,134 shares Expires 2031-02-22 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. Read SEC document |
| May 10, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 426 | $1.58 | $671.42 |
DisclosureSEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,460 F2 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,101 | $1.57 | $1,724.61 |
DisclosureSEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,886 F2 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023965 · form4.xml · derivative · entry 5 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,675 Underlying: Common Stock · 3,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023965 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,161 Underlying: Common Stock · 1,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 8,614 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010027 · form4.xml · derivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 Underlying: Common Stock · 8,614 shares Expires 2033-02-28 F1 · derivative.exercise_date: This option vested in full on March 1, 2023. Under the Issuer's 2022 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2022 in the form of a fully-vested option. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,852 | $1.80 | $3,331.93 |
DisclosureSEC source: 0001140361-23-006077 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,933 F2 · kind: These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006077 · form4.xml · derivative · entry 5 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,351 Underlying: Common Stock · 3,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006077 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,539 Underlying: Common Stock · 1,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 113,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006077 · form4.xml · derivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,021 Underlying: Common Stock · 113,021 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,053 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-006077 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| November 10, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 698 | $1.02 | $710.22 |
DisclosureSEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,732 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 882 | $1.04 | $918.87 |
DisclosureSEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,430 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041078 · form4.xml · derivative · entry 5 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,026 Underlying: Common Stock · 3,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041078 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,917 Underlying: Common Stock · 1,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,549 | $2.53 | $3,916.18 |
DisclosureSEC source: 0001140361-22-029134 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,258 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029134 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,702 Underlying: Common Stock · 3,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029134 · form4.xml · derivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,295 Underlying: Common Stock · 1,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-029134 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| May 10, 2022 Filed May 12, 2022 01:41 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,467 | $1.83 | $2,684.61 |
DisclosureSEC source: 0001140361-22-018732 · form4.xml · nonDerivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,753 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:41 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018732 · form4.xml · derivative · entry 4 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,377 Underlying: Common Stock · 3,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:41 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018732 · form4.xml · derivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,674 Underlying: Common Stock · 1,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:41 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-018732 · form4.xml · nonDerivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:47 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 5,845 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 3 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,845 Underlying: Common Stock · 5,845 shares Expires 2032-03-09 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:47 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 5,615 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,230 Underlying: Common Stock · 5,615 shares Expires 2029-03-21 F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option. F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,615 shares underlying the option. F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option. F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,615 shares underlying the option. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:09 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 22,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004587 · form4.xml · derivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,053 Underlying: Common Stock · 22,053 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:09 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 22,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004587 · form4.xml · derivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,052 Underlying: Common Stock · 22,052 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:27 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 1,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000905148-21-000542 · form4.xml · derivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: This option vests in a series of sixty (60) successive equal monthly installments measured from March 12, 2021, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| February 23, 2021 Filed Mar 14, 2022 21:47 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 5,615 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,615 Underlying: Common Stock · 5,615 shares Expires 2029-03-21 F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option. F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,615 shares underlying the option. F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option. F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,615 shares underlying the option. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 5,155 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 2 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,155 Underlying: Common Stock · 5,155 shares Expires 2031-02-22 F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 25,134 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000512 · form4.xml · derivative · entry 1 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,134 Underlying: Common Stock · 25,134 shares Expires 2031-02-22 F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,327 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-20-029017 · form4.xml · derivative · entry 18 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,258 Underlying: Common Stock · 4,327 shares Expires 2030-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2020. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,984 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-20-029017 · form4.xml · derivative · entry 17 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,655 Underlying: Common Stock · 10,984 shares Expires 2028-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vests twenty-one sixtieths (21/60ths) on October 1, 2020, the remaining balance vests in 39 successive, equal monthly installments measured from October 1, 2020. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 12,285 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001140361-20-029017 · form4.xml · derivative · entry 16 Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,773 Underlying: Common Stock · 12,285 shares Expires 2028-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.